What makes Neoimmunetech unique isn't just another immunotherapy platform—it's their focus on 'homeostatic T-cell proliferation' and 'T-cell stemness induction.' While competitors chase incremental improvements in existing modalities, Neoimmunetech is exploring how to make T-cells more like stem cells: self-renewing, persistent, and capable of sustained anti-tumor activity. Their research suggests their approach could work synergistically with other cancer treatments, potentially turning 'cold' tumors 'hot.'

Here's the telling detail: 52% of their traffic is direct. This isn't a company burning cash on SEO or content marketing. When people visit neoimmunetech.com, they're looking for it specifically. The top keyword is their own brand name (760 monthly searches), followed by their lead candidate 'NT-I7' (320 searches). This suggests a focused, professional audience—likely investors, partners, and researchers—rather than broad public interest. The 100% traffic from 'undefined' (likely South Korea) confirms their regional focus.

For investors, Neoimmunetech represents a classic 'stealth biotech' profile: real revenue, focused science, and experienced leadership without the hype. The $7.9M revenue on 51 employees suggests efficient operations. The lack of funding announcements might mean they're self-sustaining or have private backing. The real question isn't about their web traffic—it's about their clinical data. With NT-I7 in the spotlight, the next 12-18 months will be critical for validating their T-cell stemness approach.